Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for OptimizeRx (OPRX) over the last 15 years, with FY2024 value amounting to $171.2 million.

  • OptimizeRx's Liabilities and Shareholders Equity rose 310.05% to $170.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $678.5 million, marking a year-over-year decrease of 276.49%. This contributed to the annual value of $171.2 million for FY2024, which is 665.63% down from last year.
  • Per OptimizeRx's latest filing, its Liabilities and Shareholders Equity stood at $171.2 million for FY2024, which was down 665.63% from $183.4 million recorded in FY2023.
  • OptimizeRx's Liabilities and Shareholders Equity's 5-year high stood at $183.4 million during FY2023, with a 5-year trough of $60.3 million in FY2020.
  • For the 5-year period, OptimizeRx's Liabilities and Shareholders Equity averaged around $138.1 million, with its median value being $141.0 million (2021).
  • In the last 5 years, OptimizeRx's Liabilities and Shareholders Equity surged by 13369.87% in 2021 and then crashed by 665.63% in 2024.
  • OptimizeRx's Liabilities and Shareholders Equity (Annual) stood at $60.3 million in 2020, then soared by 133.7% to $141.0 million in 2021, then dropped by 4.49% to $134.7 million in 2022, then soared by 36.18% to $183.4 million in 2023, then decreased by 6.66% to $171.2 million in 2024.
  • Its Liabilities and Shareholders Equity was $171.2 million in FY2024, compared to $183.4 million in FY2023 and $134.7 million in FY2022.